At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 136 enrolled
Drug / intervention
CVN424 Low Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
In Brief
A Phase 2 clinical trial evaluating CVN424 Low Dose, CVN424 High Dose, and 1 other intervention for Parkinson Disease. Completed, enrolled 136 participants across 21 sites.
Detailed Summary
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionNov 2021
Study CompletionDec 2021
TodayJul 2026
First PostedDec 10, 2019
Enrollment StartDec 2, 2019
Primary CompletionNov 6, 2021
Study CompletionDec 13, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.6 years ago
Interventions
CVN424 Low Dosedrug
CVN424
CVN424 High Dosedrug
CVN424
Placebodrug
Placebo